Journal of Clinical and Aesthetic Dermatology

Updates on Psoriasis & Cutaneou Oncology

An evidence-based, peer-reviewed journal for practicing clinicians in the field of dermatology

Issue link: http://jcadonline.epubxp.com/i/882293

Contents of this Issue

Navigation

Page 36 of 43

S37 P r o c e e D i n G s JCAD jOUrnAl Of ClInICAl And AEsthEtIC dErMAtOlOgy september 2017 • volume 10 • number 9 • supplement (resurface 1 and resurface 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390(10091):276–288. 7. Blauvelt a, Papp Ka, Grieths ce, et al. eecacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase iii, double- blinded, placebo- and active comparator-controlled voyaGe 1 trial. J Am Acad Dermatol. 2017;76(3):405– 417. 8. reich K, armstrong aW, foley P, et al. eecacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase iii, double-blind, placebo- and active comparator-controlled voyaGe 2 trial. J Am Acad of Dermatol. 2017;76(3):418–431. 9. Krueger JG, ferris lK, Menter a, et al. anti-il-23a mab Bi 655066 for treatment of moderate-to-severe psoriasis: safety, eecacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2015;136(1):116–124 e117. 10. lonnberg as, Zachariae c, skov l. targeting of interleukin-17 in the treatment of psoriasis. Clin Cosmet Investig Dermatol. 2014;7:251–259. 11. Jancin B. secukinumab for psoriasis at 4 years: undiminished eecacy and safety. 18 oct 2016; http://www.mdedge.com/edermatologynews/article/1 15936/psoriasis/secukinumab-psoriasis-4-years- undiminished-eecacy-and. accessed april 30, 2017. 12. Gordon KB, Blauvelt a, Papp Ka, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345–356. 13. lebwohl M, strober B, Menter a, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318–1328. 14. Background Package for Bla 761032 siliq (brodalumab) injection, 210 mg/1.5 ml [fDa briefng document]. silver spring, MD: food and Drug administration center for Drug evaluation and research oece of new Drugs; 19 Jul 2016. https://www.fda.gov/downloads/advisorycommittees/c ommitteesmeetingmaterials/drugs/dermatologicandop hthalmicdrugsadvisorycommittee/ucm511357.pdf. accessed 30 apr 2017. 15. Gupta Ma, schork nJ, Gupta aK, Kirkby s, ellis cn. suicidal ideation in psoriasis. int J Dermatol. 1993;32(3):188–190. 16. armstrong aW, siegel MP, Bagel J, et al. from the medical board of the national Psoriasis foundation: treatment targets for plaque psoriasis. J Am Acad Dermatol. 2017;76(2):290–298. 17. citrome l, Ketter ta. When does a diderence make a diderence? interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Int J Clin Pract. 2013;67(5):407–411. 18. Kristensen le, Jorgensen ts, christensen r, et al. societal costs and patients' experience of health inequities before and after diagnosis of psoriatic arthritis: a Danish cohort study. Ann Rheum Dis. 2017;76(9):1495–1501. 19. spelman l, su Jc, fernandez-Penas P, et al. frequency of undiagnosed psoriatic arthritis among psoriasis patients in australian dermatology practice. J Eur Acad Dermatol Venerol. 2015;29(11):2184–2191. 20. faustini f, simon D, oliveira i, et al. subclinical joint ingammation in patients with psoriasis without concomitant psoriatic arthritis: a cross-sectional and longitudinal analysis. Ann Rheum Dis. 2016;75(12):2068–2074. 21. antonelli a, ferrari sM, Giuggioli D, ferrannini e, ferri c, fallahi P. chemokine (c-x-c motif ) ligand (cxcl)10 in autoimmune diseases. Autoimmun Rev. 2014;13(3):272– 280. 22. abji f, Pollock ra, liang K, chandran v, Gladman DD. Brief report: cxcl10 is a possible biomarker for the development of psoriatic arthritis among patients with psoriasis. Arthritis Rheumatol. 2016;68(12):2911-2916. 23. lewinson rt, vallerand ia, lowerison MW, et al. Depression is associated with an increased risk of psoriatic arthritis among patients with psoriasis: a population-based study. J Invest Dermatol. 2017;137(4):828–835. 24. tillett W, de-vries c, McHugh nJ. Work disability in psoriatic arthritis: a systematic review. Rheumatology (oxford). 2012;51(2):275–283. 25. tillett W, shaddick G, Jobling a, et al. edect of anti-tnf and conventional synthetic disease-modifying anti- rheumatic drug treatment on work disability and clinical outcome in a multicentre observational cohort study of psoriatic arthritis. Rheumatology (Oxford). 2017;56(4):603–612. 26. 26. iannone f, lopalco G, rigante D, orlando i, cantarini l, lapadula G. impact of obesity on the clinical outcome of rheumatologic patients in biotherapy. Autoimmun Rev. 2016;15(5):447–450. 27. Di lernia v, tasin l, Pellicano r, Zumiani G, albertini G. impact of body mass index on retention rates of anti- tnf-alfa drugs in daily practice for psoriasis. J Dermatolog Treat. 2012;23(6):404–409. 28. Hojgaard P, Glintborg B, Kristensen le, Gudbjornsson B, love tJ, Dreyer l. the inguence of obesity on response to tumour necrosis factor-alpha inhibitors in psoriatic arthritis: results from the DanBio and iceBio registries. Rheumatology (Oxford). 2016;55(12):2191–2199. 29. Kirkham BW, Kavanaugh a, reich K. interleukin-17a: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology. 2014;141(2):133–142. 30. craven J. sustained improvements in Psa domains with secukinumab. 14 nov 2016; http://www.clinicaladvisor.com/acr-2016- coverage/three-year-clinical-improvement-in-psoriatic- arthritis-with-secukinumab/article/572636/. accessed 2 May 2017. 31. Mease P, Genovese Mc, Gladstein G, et al. abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase ii trial. Arthritis Rheum. 2011;63(4):939–948. 32. Ghoreschi K, Gadina M. Jakpot! new small molecules in autoimmune and ingammatory diseases. Exp Dermatol. 2014;23(1):7–11. 33. Mease P, Hall s, fitzgerald o, et al. eecacy and safety of tofacitinib, an oral janus kinase inhibitor, or adalimumab in patients with active psoriatic arthritis and an inadequate response to conventional synthetic dmards: a randomized, placebo-controlled, Phase 3 trial. abstract 2983. Presented at the american college of rheumatology Meeting; 15 nov 2016. 34. Gladman D, rigby W, azevedo v, et al. eecacy and safety of tofacitinib, an oral janus kinase inhibitor, in patients with active psoriatic arthritis and an inadequate response to tumor necrosis factor inhibitors: oPal beyond, a randomized, double-blind, placebo- controlled, Phase 3 trial. abstract 10l. american college of rheumatology Meeting; 15 nov 2016. 35. fowler Jf, Jr., Hebert aa, sugarman J. DfD-01, a novel medium potency betamethasone dipropionate 0.05% emollient spray, demonstrates similar eecacy to augmented betamethasone dipropionate 0.05% lotion for the treatment of moderate plaque psoriasis. J Drugs Dermatol. 2016;15(2):154–162. 36. Menter a, Korman nJ, elmets ca, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. J Am Acad Dermatol. 2009;60(4):643–659. 37. lebwohl M, siskin sB, epinette W, et al. a multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. J Am Acad of Dermatol. 1996;35(2 Pt 1):268– 269. 38. lebwohl M, yoles a, lombardi K, lou W. calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: edects on the duration of improvement. J Am Acad of Dermatol. 1998;39(3):447– 450. 39. Kaufmann r, Bibby aJ, Bissonnette r, et al. a new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an edective once-daily treatment for psoriasis vulgaris. Dermatology. 2002;205(4):389–393. 40. Kubin Me, Kokkonen n, Palatsi r, et al. clinical eeciency of topical calcipotriol/betamethasone treatment in psoriasis relies on suppression of the ingammatory tnfalpha - il-23 - il-17 axis. Acta Derm Venereol. 2017;97(4):449–455. 41. Koo J, tyring s, Werschler WP, et al. superior eecacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris - a randomized phase ii study. J Dermtolog Treat. 2016;27(2):120–127. 42. lebwohl MG, Breneman Dl, Gode Bs, et al. tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. J Am Acad Dermatol. 1998;39(4 Pt 1):590–596. 43. sugarman Jl, Gold ls, lebwohl MG, Pariser DM, alexander BJ, Pillai r. a Phase 2, multicenter, double- blind, randomized, vehicle controlled clinical study to assess the safety and eecacy of a

Articles in this issue

Links on this page

Archives of this issue

view archives of Journal of Clinical and Aesthetic Dermatology - Updates on Psoriasis & Cutaneou Oncology